Dermatology and Safety - Esthetician Leadership Today

Cosmetic Dermatology in the Digital Age: How to Harness Technology and Uphold Safety and Ethics

The Dermatology Digest

DECEMBER 6, 2024

Artificial intelligence (AI), augmented reality, social media, telehealth, and other emerging technologies are changing the way that healthcare is delivered, and cosmetic dermatology is no exception. She believes some conditions, consultations, and procedures require in-person appointments to ensure safety and accuracy.

Ethics

Ethics Social Media Safety Technology

Important Updates on the Efficacy and Safety of JAK Inhibitors in Dermatology

The Dermatology Digest

DECEMBER 24, 2024

Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, reviews the latest efficacy and safety data on oral and topical Janus kinase (JAK) inhibitors used in dermatology. He spoke on this topic at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference.

Safety

Safety Dermatology Dermatitis Medical

Q&A: Reframing JAK Inhibitor Safety and Flexibility in AD With Leon Kircik, MD

Dermatology Times

JUNE 7, 2025

At the 2025 Revolutionizing Atopic Dermatitis Conference, Leon Kircik, MD, highlighted the safety of JAK inhibitors, clarified misconceptions around boxed warnings, and discussed the clinical relevance of recent label updates for abrocitinib.

Safety

Safety Dermatitis Clinic

Best Practices for Your Workout After Botox: Safety Tips and Recommendations

US Dermatologt Partners

MAY 26, 2025

Dermatology Partners of Plano. The post Best Practices for Your Workout After Botox: Safety Tips and Recommendations appeared first on U.S. Dermatology Partners. “It’s a quick procedure with minimal downtown, so patients can get back to their everyday routines almost immediately.

Safety

Safety Facials Injections Training

Late Breaking Data: Lebrikizumab Demonstrates Efficacy in AD Patients with Skin of Color

Dermatology Times

JUNE 7, 2025

The safety profile was favorable, with mild to moderate adverse effects and no serious events requiring drug discontinuation. By week 24, 78.4% achieved EASI 75, and 54.1% reached IGA 0/1, with notable improvements in hyperpigmentation.

Eczema

Eczema Dermatitis Safety Rosacea

Late-Breaking Data: Flexible Dosing of Abrocitinib for AD Shows Real-World Promise

Dermatology Times

JUNE 10, 2025

Safety and Adverse Events Treatment-emergent adverse events (TEAEs) led to dose reductions in 8.7% (n=27) of participants and dose escalations in 3.8% (n=12). Interestingly, the majority of participants remained on their initial dose throughout the study: 65.0% in the 100 mg group and 62.0% in the 200 mg group.

Eczema

Eczema Dermatitis Rosacea Safety

Icotrokinra Shows Efficacy and Safety in Adolescents With Moderate to Severe PsO

The Dermatology Digest

APRIL 10, 2025

These data were presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting in Buenos Aires, Argentina. ” Icotrokinra demonstrated a favorable safety profile. In the study, 84.1% achieved a Psoriasis Area and Severity Index (PASI) 90 response, compared to 27.3% and Janssen Biotech, Inc.,

Safety

Safety Therapy Dermatology Hospital

U.S. FDA Approves Bimekizumab-bkzx (Bimzelx, UCB) for HS

The Dermatology Digest

NOVEMBER 20, 2024

Kimball, MD, MPH, Beth Israel Deaconess Medical Center and Professor of Dermatology at Harvard Medical School, Boston, MA, in s news release. “In the Phase 3 clinical studies, patients treated with bimekizumab-bkzx achieved deep and sustained clinical responses up to 48 weeks.” Clinical responses were sustained to Week 48.

Safety

Safety Sustainability Clinic Medical

ASCO Skin Cancer News: Lifileucel Boosts Five-year Survival Rates in Advanced Melanoma

The Dermatology Digest

MAY 23, 2025

Adverse events (AEs) were consistent with known safety profiles of nonmyeloablative lymphodepletion and interleukin-2 administration. These five-year data represent the longest follow-up in a multicenter TIL therapy study, reinforcing the deep and lasting responses, and favorable long-term safety with Amtagvi.

Safety

Safety Therapy Office Clinic

Navigating Pregnancy, Dermatology, and Drug Safety

Dermatology Times

FEBRUARY 19, 2024

Katherine Economy, MD, discusses the challenges and opportunities of treating pregnant patients with dermatologic conditions, emphasizing the importance of comprehensive medication reviews, patient-centered decision-making, and the need for including pregnant patients in clinical trials.

Safety

Safety Dermatology Clinic Medical

Beyond the Clinic: How the Mobile Destination Healthy Skin Initiative Saved Peter Graylin’s Life

Dermatology Times

MAY 28, 2025

Peter Graylin shares his transformative skin cancer journey, emphasizing the importance of early detection, sun safety, and accessible dermatology programs.

Clinic

Clinic Safety Dermatology

Day 1 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Dermatology Times

JUNE 6, 2025

The conference will highlight the clinical integration of newly approved biologics nemolizumab and lebrikizumab in atopic dermatitis treatment. The SCALE UP study will demonstrate upadacitinib's effectiveness in providing symptom relief across various skin types and racial groups.

Dermatitis

Dermatitis Eczema Rosacea Skin Types

New Five-year Study Backs Deucravacitinib’s Safety and Efficacy in PsO

The Dermatology Digest

FEBRUARY 25, 2025

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed consistent safety and efficacy in patients with in moderate-to-severe plaque psoriasis for up to five years, new research shows. Moreover, the safety profile of deucravacitinib remained consistent through five years with no new safety signals identified.

Safety

Safety Sustainability Clinic Dermatology

Phase 3 Data: “Game-changing” Oral IL-23 Blocker Shows Efficacy and Safety in PsO

The Dermatology Digest

MARCH 14, 2025

No safety signals emerged through Week 24. link] ICYMI: Kenneth Gordon, MD, Professor and Chair of Dermatology at the Medical College of Wisconsin inMilwaukee, WI, reviews the encouraging efficacy data onicotrokinraat Maui Derm Caribbean 2025. Now, I will be able to offer icotrokinra vs, injectable IL23 and not compromise efficacy.”

Safety

Safety Injections Dermatology Clinic

Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria

Dermatology Times

JUNE 9, 2025

Further large-scale studies are needed to confirm barzolvolimab's efficacy and safety in chronic inducible urticaria. The treatment was generally well-tolerated, with mild to moderate adverse events and no cumulative toxicity observed.

Eczema

Eczema Rosacea Dermatitis Safety

HA Filler News: Evolysse Form and Evolysse Smooth Show Long-term Safety and Efficacy for Smile Lines

The Dermatology Digest

MAY 22, 2025

The multicenter, randomized, controlled, double-blind study followed 140 patients through 12 months and evaluated the long-term safety and effectiveness of Evolysse Form and Evolysse Smooth for the correction of moderate to severe dynamic facial wrinkles and folds. in the control arm.

Safety

Safety Sustainability Injections Office

Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis

Dermatology Times

APRIL 11, 2025

Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumabs 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use.

Safety

Safety Sustainability

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

Dermatology Times

SEPTEMBER 26, 2023

Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.

Safety

Safety Dermatitis Treatments

U.S. FDA Approves Celltrion’s STELARA Biosimilar

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. Lebwohl, MD, Professor and Systemn Chaior of Dermatology at Icahn School of Medicine at Mount Sinai in New York, NY. Celltrion Inc. The post U.S.

Portfolios

Portfolios Injections Office Safety

DEBRA Research, Dermaliq Team Up to Advance Cutaneous Drug Delivery for EB

The Dermatology Digest

MAY 28, 2025

With its unique features and exceptional safety profile, hyliQ is ideally suited for the touchless topical treatment of disease-affected and damaged skin. The post DEBRA Research, Dermaliq Team Up to Advance Cutaneous Drug Delivery for EB appeared first on The Dermatology Digest.

Partnerships

Partnerships Therapy Technology Safety

Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data

Dermatology Times

OCTOBER 1, 2024

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Safety

Safety Clinic

Late-Breaking Data: Positive Outcomes in AD Patients with Skin of Color Using Dupilumab

Dermatology Times

JUNE 11, 2025

The goal of the open-label, single-arm DISCOVER study was to further evaluate the efficacy and safety of dupilumab when used as a monotherapy in this patient group Methods Eligible participants in the analysis ( n = 120) were aged ≥12 years with Fitzpatrick skin types IV (43%), V (48%), and VI (9%).

Eczema

Eczema Dermatitis Rosacea Safety

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections

Injections Medical Portfolios Branding

Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Dermatology Times

JUNE 7, 2025

JAK inhibitors' safety and recent label updates were discussed, addressing misconceptions and clinical relevance. Shared inflammatory mechanisms between atopic dermatitis and alopecia areata were emphasized, highlighting the need for clinician awareness.

Dermatitis

Dermatitis Eczema Rosacea Management

Proposed FDA Rule Calls for Testing for Asbestos in Talc Cosmetic Products

The Dermatology Digest

DECEMBER 29, 2024

We believe that the proposed testing techniques are appropriate methods to detect asbestos to help ensure the safety of talc-containing cosmetic products. The post Proposed FDA Rule Calls for Testing for Asbestos in Talc Cosmetic Products appeared first on The Dermatology Digest.

Cosmetic Products

Cosmetic Products Office Safety Dermatology

Inside IL-17 Inhibitors Advancing Psoriasis Care

Dermatology Times

JUNE 18, 2025

06) Volume 46 Issue 06 Inside IL-17 Inhibitors Advancing Psoriasis Care Author(s): Maddi Hebebrand, MC, Associate Editor Explore the latest insights on IL-17 inhibitors for psoriasis, highlighting their mechanisms, real-world benefits, and future treatment strategies.

Eczema

Eczema Safety Rosacea Dermatitis

Christina Feser, DO, Shares Therapeutic Advances in Hidradenitis Suppurativa From SCALE 2025

Dermatology Times

JUNE 17, 2025

Dermatology Times sat down with Feser to discuss key takeaways from her talk and the promising future of HS care. At the 2025 Music City SCALE meeting held May 14-18 in Nashville, Tennessee, dermatologist Christina Feser, DO, FAAD, FAOCD, delivered an information-packed presentation titled “Therapeutic Updates for Hidradenitis Suppurativa.”

Eczema

Eczema Rosacea Dermatitis Management

FDA Approves First Targeted Therapy for CSU in More Than a Decade

The Dermatology Digest

APRIL 18, 2025

The post FDA Approves First Targeted Therapy for CSU in More Than a Decade appeared first on The Dermatology Digest.

Therapy

Therapy Safety Dermatology Medical

Michael Gold, MD: Mastering Device Complications and the Importance of Preparedness in Dermatology

Dermatology Times

MARCH 9, 2025

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

Dermatology

Dermatology Safety Management

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Dermatology Times

MAY 20, 2025

A melanoma survivor shares her journey, emphasizing the importance of sun safety and regular skin exams to prevent skin cancer.

Education

Education Safety

Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial

Dermatology Times

MAY 16, 2024

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Safety

Safety Sustainability

Late Breaking Data: Long-Term Safety and Efficacy of Nemolizumab for AD

Dermatology Times

JUNE 10, 2025

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

Safety

Safety Dermatitis

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology

The Dermatology Digest

JULY 24, 2024

The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology appeared first on The Dermatology Digest.

Dermatology

Dermatology Sales Marketing Safety

Alys Pharmaceuticals Submits ALY-301 Clinical Trial Application in Germany for Cold Urticaria

Dermatology Times

JUNE 12, 2025

1 The study will assess the efficacy and safety of the mast cell selective c-Kit inhibitor in the subtype of chronic inducible urticaria.

Pharmaceutical

Pharmaceutical Clinic Eczema Rosacea

ASDSA Study Highlights Lack of On-site Physician Supervision in Las Vegas Medical Spas

The Dermatology Digest

JANUARY 8, 2025

Medical spas in Las Vegas, NV, lack on-site physician supervision, according to a study by the the American Society for Dermatologic Surgery Association (ASDSA). The post ASDSA Study Highlights Lack of On-site Physician Supervision in Las Vegas Medical Spas appeared first on The Dermatology Digest.

Medical

Medical Social Media Safety Training

Larry Eichenfield, MD: Safety, Convenience, and Future Role of Icotrokinra in Treating Adolescent Psoriasis

Dermatology Times

APRIL 21, 2025

Eichenfield discusses safety, lab monitoring, and treatment positioning of icotrokinra in adolescents with moderate to severe plaque psoriasis.

Safety

Safety Treatments

Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in AD Patients After 1 Year

Dermatology Times

JUNE 18, 2025

Common adverse effects were observed, but no new safety concerns were identified for either drug. After one year, both drugs showed high efficacy rates, with abrocitinib achieving slightly better outcomes in some measures.

Eczema

Eczema Dermatitis Rosacea Safety

Artificial Intelligence Dermatology Mobile Apps Present Critical Risks and Inconsistencies, JAMA Study Reports

Dermatology Times

MARCH 19, 2024

AI mobile apps have critical gaps in efficacy, safety, and transparency, according to a new report.

Safety

Safety Dermatology

Nemolizumab (Nemluvio, Galderma) Shows Sustained Improvements in Itch and Lesions in PN

The Dermatology Digest

JUNE 18, 2025

The research will be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) in Rome, Italy. The post Nemolizumab (Nemluvio, Galderma) Shows Sustained Improvements in Itch and Lesions in PN appeared first on The Dermatology Digest.

Sustainability

Sustainability Safety Hospital Dermatology

Nemolizumab (Nemluvio, Galderma) Shows “Sustained and Increased” Improvements in Itch and Skin Lesions in AD Patients for Up to Two Years

The Dermatology Digest

JUNE 6, 2025

Nemolizumab (Nemluvio, Galderma) produces sustained and increased improvements in atopic dermatitis (AD) symptoms, including itch and skin lesions for up to two years with no new safety signals identified, according to data from a new interim analysis of a long-term extension study.

Sustainability

Sustainability Dermatitis Safety Eczema

Investigating Roflumilast 0.05% Cream for Infant AD with Mercedes E. Gonzalez, MD

Dermatology Times

JUNE 17, 2025

The trial evaluates the safety, efficacy, and tolerability of roflumilast cream, potentially offering a novel therapeutic pathway for early intervention in AD. Current treatments for infant AD are predominantly topical corticosteroids, highlighting the need for non-steroidal options like roflumilast cream.

Eczema

Eczema Dermatitis Rosacea Safety

AnaptysBio Drops AD Drug After Phase 2 Trial Misses Its Marks

The Dermatology Digest

DECEMBER 11, 2024

Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.

Safety

Safety Dermatitis Therapy Dermatology

Fostering Patient Wellness: Prioritizing Safety and Education in PDE4 Utilization

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety

Safety Education Therapy Management

Cosmetic Dermatology in the Digital Age: How to Harness Technology and Uphold Safety and Ethics

Important Updates on the Efficacy and Safety of JAK Inhibitors in Dermatology

Trending Sources

Q&A: Reframing JAK Inhibitor Safety and Flexibility in AD With Leon Kircik, MD

Best Practices for Your Workout After Botox: Safety Tips and Recommendations

Late Breaking Data: Lebrikizumab Demonstrates Efficacy in AD Patients with Skin of Color

Late-Breaking Data: Flexible Dosing of Abrocitinib for AD Shows Real-World Promise

Icotrokinra Shows Efficacy and Safety in Adolescents With Moderate to Severe PsO

U.S. FDA Approves Bimekizumab-bkzx (Bimzelx, UCB) for HS

ASCO Skin Cancer News: Lifileucel Boosts Five-year Survival Rates in Advanced Melanoma

Navigating Pregnancy, Dermatology, and Drug Safety

Beyond the Clinic: How the Mobile Destination Healthy Skin Initiative Saved Peter Graylin’s Life

Day 1 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

New Five-year Study Backs Deucravacitinib’s Safety and Efficacy in PsO

Phase 3 Data: “Game-changing” Oral IL-23 Blocker Shows Efficacy and Safety in PsO

Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria

HA Filler News: Evolysse Form and Evolysse Smooth Show Long-term Safety and Efficacy for Smile Lines

Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

U.S. FDA Approves Celltrion’s STELARA Biosimilar

DEBRA Research, Dermaliq Team Up to Advance Cutaneous Drug Delivery for EB

Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data

Late-Breaking Data: Positive Outcomes in AD Patients with Skin of Color Using Dupilumab

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Proposed FDA Rule Calls for Testing for Asbestos in Talc Cosmetic Products

Inside IL-17 Inhibitors Advancing Psoriasis Care

Christina Feser, DO, Shares Therapeutic Advances in Hidradenitis Suppurativa From SCALE 2025

FDA Approves First Targeted Therapy for CSU in More Than a Decade

Michael Gold, MD: Mastering Device Complications and the Importance of Preparedness in Dermatology

Top 5 Articles of the Week: June 8-13

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial

Late Breaking Data: Long-Term Safety and Efficacy of Nemolizumab for AD

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology

Alys Pharmaceuticals Submits ALY-301 Clinical Trial Application in Germany for Cold Urticaria

ASDSA Study Highlights Lack of On-site Physician Supervision in Las Vegas Medical Spas

Larry Eichenfield, MD: Safety, Convenience, and Future Role of Icotrokinra in Treating Adolescent Psoriasis

Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in AD Patients After 1 Year

Artificial Intelligence Dermatology Mobile Apps Present Critical Risks and Inconsistencies, JAMA Study Reports

Nemolizumab (Nemluvio, Galderma) Shows Sustained Improvements in Itch and Lesions in PN

Nemolizumab (Nemluvio, Galderma) Shows “Sustained and Increased” Improvements in Itch and Skin Lesions in AD Patients for Up to Two Years

Investigating Roflumilast 0.05% Cream for Infant AD with Mercedes E. Gonzalez, MD

AnaptysBio Drops AD Drug After Phase 2 Trial Misses Its Marks

Fostering Patient Wellness: Prioritizing Safety and Education in PDE4 Utilization

Stay Connected